Treasury gets $975M venture fund with no public oversight rules
H.R. 6412 — Independence Investment Fund Act · Filed by Pete Sessions (R-TX) · 6 cosponsors · Introduced Dec 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new federal investment fund within the Treasury Department to invest in U.S. companies developing critical technologies (like biotech, AI, semiconductors) that strengthen national security or economic competitiveness. The fund will make equity investments of $1–10 million per company, operate like a venture capital firm, and aim to generate financial returns to sustain itself while also signaling to private investors which technologies matter to the government. It authorizes $975.5 million for 2025 (including $300 million for biotech) and exempts the fund from standard federal procurement and administrative review rules.
Why we flagged it
The bill establishes a federal venture capital vehicle ostensibly for national security technology investment, but its core mechanism is the creation of a Treasury-managed fund with broad discretion, minimal public oversight, and explicit exemptions from standard federal administrative and procurement rules—making it functionally a deregulated investment authority rather than a transparent public program.
What the text implies
- Section 7 exempts all Secretary actions from the Administrative Procedure Act (APA) and Paperwork Reduction Act, eliminating public notice-and-comment rulemaking and FOIA-like transparency requirements—a significant governance carve-out that may insulate investment decisions from judicial review or public scrutiny.
- The managing entity is explicitly 'not a Federal agency' (Section 4), creating a quasi-private structure that may operate with fewer transparency and conflict-of-interest safeguards than traditional government programs, despite deploying federal capital.
The full analysis lists 5 implications of this text.
Who stands to gain
venture capital firms (as potential managing entities); early-stage technology companies in biotech, semiconductors, AI, and critical emerging tech sectors; private equity and investment management firms with experience in strategic venture capital